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Abstract Recombinant Plasmodium falciparum glyoxalase I
(PfGlx I) was characterized as monomeric Zn2+-containing en-
zyme of 44 kDa. The KM value of the methylglyoxal^gluta-
thione adduct is 77 * 15 WM, the kcat value being 4000 min31
at 25‡C and pH 7.0. PfGlx I consists of two halves, each of
which is homologous to the small 2-domain glyoxalase I of man.
Both parts of the pfglx I gene were overexpressed; the C-ter-
minal half of PfGlx I was found to be a stable protein and
formed an enzymatically active dimer. These results support
the hypothesis of domain-swapping and subunit fusion as mech-
anisms in glyoxalase I evolution.
5 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The cytosolic glyoxalase system comprises two enzymes,
glyoxalase I (Glx I; EC 4.4.1.5) and glyoxalase II (Glx II;
EC 3.1.2.6), and converts toxic 2-oxoaldehydes into 2-hy-
droxycarboxylic acids, using reduced glutathione (GSH) as a
coenzyme (see [1] for review and references therein). Glx I
belongs to the VOC metalloenzyme superfamily [2,3] the
members of which contain a paired LKLLL motif providing
for a metal coordination environment [4^6]. Human Glx I is a
zinc-dependent homodimeric enzyme. Each subunit consists
of two similar domains and appears to have arisen from a
gene duplication event [4]. In yeasts [7] and plants [4,8,9],
however, glyoxalases I were detected that are doubled in
size and thus consist of four homologous domains indicating
a further gene duplication with an additional gene fusing
event. This hypothesis was supported by studies on yeast
Glx I which included modelling, mutagenesis, and functional
analysis and suggest that the enzyme has two active sites
contained in a single polypeptide [10].
The malarial parasite Plasmodium falciparum is responsible
for more than 2 million deaths per year. Due to increasing
resistances against the presently available drugs, new thera-
peutic approaches directed against novel targets are urgently
required [11^13]. The glyoxalase detoxi¢cation system is of
particular importance to organisms largely depending on gly-
colytic energy production such as tumor cells [14] and malar-
ial parasites. P. falciparum consumes more than 100-fold more
glucose than its host erythrocyte, and correspondingly, has to
cope with large quantities of the toxic by-product methyl-
glyoxal. In erythrocytes infected with P. falciparum the for-
mation of D-lactate from methylglyoxal was found to be in-
creased by a factor of 30. Inhibitors of Glx I have been shown
to exhibit antiproliferative e¡ects on malignant cell lines as
well as on parasites [15,16]. S-p-Bromobenzylglutathione ethyl
diester for instance inhibits the growth of malarial parasites in
vitro with an IC50 of approximately 5 WM 6 h after exposure
[1,17]. Taken together, these facts render the glyoxalase sys-
tem of P. falciparum a promising target for the development
of novel antimalarial drugs [18^21].
Here we provide ¢rst insight into the malarial glyoxalase
system and substantiate the hypothesis that large glyoxalases,
like the protein from P. falciparum, evolved from small ho-
modimeric glyoxalases by a second gene duplication event.
2. Materials and methods
2.1. Materials
All chemicals used were of the highest available purity and were
obtained from Roth (Karlsruhe, Germany), Merck (Frankfurt/M.,
Germany) or Sigma/Aldrich (Steinheim, Germany). The expression
system QIA-express was purchased from Qiagen (Hilden, Germany).
Sequencing reactions were carried out on an ABI Prism 310 Genetic
Analyzer.
2.2. Molecular biology
The complete open reading frame of a Glx I-like gene was identi¢ed
on chromosome 11 by online screening of the P. falciparum genome
sequencing project (www.ncbi.nlm.nih.gov/Malaria/plasmodium-
blcus.html; [22]). Two homologous primers ^ introducing a BamHI
and a HindIII restriction site (underlined) ^ were derived from this
gene: N-terminal PfGlxf1 5P-CGCGGGATCCGCACAAGAAATAT-
CAAATTTAG-3P, C-terminal PfGlxr1 5P-CGCGAAGCTTTTATTT-
TGCAATAAATGAAGTG-3P. The polymerase chain reaction (PCR)
using a gametocyte cDNA library as template was carried out with
Taq polymerase (3 min at 94‡C; 94‡C, 30 s; 50‡C, 45 s; 72‡C, 90 s; 30
cycles; 72‡C, 4 min). The derived fragment of correct size was cloned
into pQE30 for sequencing and overexpression. The 5P and 3P halves
of the P. falciparum Glx I (PfGlx I) gene were subcloned analogously.
The Escherichia coli strain M15 was used for overexpressing the
three inserts at 37‡C. The recombinant proteins were puri¢ed over a
nickel^nitrilotriacetic acid column and concentrated. Protein concen-
trations were determined at 280 nm on the basis of the calculated
respective millimolar absorption coe⁄cients.
2.3. Enzyme assays
Glx I activity was determined from the rate of formation of the
thiol ester S-D-lactoylglutathione (SLG; O240 nm = 3.37 mM31 cm31)
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[23]. The PfGlx I standard assay mixture was experimentally de¢ned as
follows: 100 mM potassium phosphate, 100 mM KCl, pH 7.0, 2 mM
methylglyoxal, and 1 mM GSH, preincubation at 25‡C for 15 min,
start with Glx I. For determining the speci¢c activity of Glx I, NiCl2
(20 WM) or ZnCl2 (250 WM) was added to the standard assay mixture
in order to guarantee saturation of the enzyme with an activating
divalent cation.
2.4. Cultivation of P. falciparum
Intraerythrocytic stages of two di¡erent chloroquine resistant
P. falciparum strains (K1, FCR3) were cultured in vitro according
to Trager and Jensen [24]. The parasites were synchronized and har-
vested, and a cell extract was prepared as previously described [25].
2.5. Immunoblotting
Rabbit antiserum raised against recombinant PfGlx I was obtained
from BioScience, Go«ttingen, Germany. Protein samples were sub-
jected to 12% sodium dodecyl sulfate^polyacrylamide gel electropho-
resis (SDS^PAGE) and blotted on a polyvinylidene di£uoride mem-
brane using a semidry blot procedure. As a second antibody,
peroxidase-conjugated swine anti-rabbit immunoglobulins (Dako Di-
agnostika, Hamburg, Germany) were used.
2.6. Metal ion analysis
Zn2þ and Ni2þ ions were determined by atom absorption spectros-
copy (Dr. V. Muntean, Seelig Analytical Laboratories, Karlsruhe,
Germany).
For fully saturating the enzyme with metal ions, 7 WM Glx I con-
taining 0.63 zinc ion per molecule in 100 mM potassium phosphate of
pH 7.0 and 4‡C was incubated overnight with 100 WM ZnCl2 and then
exhaustively dialyzed against 1 WM ZnCl2 in the same bu¡er. Subse-
quently, the protein content of the retentate was determined, and
Zn2þ concentrations were assessed by atom absorption spectroscopy.
In an analogous experiment NiCl2 was used instead of ZnCl2.
3. Results and discussion
3.1. In silico analyses and structural considerations
Alignments of the deduced amino acid sequence of PfGlx I
with the respective enzymes from other species indicated iden-
tities of up to 43% (see Fig. 1). Furthermore, the enzyme has
twice the size of 2-domain glyoxalases for which Glx I from
man is the most prominent example. In the homodimeric hu-
Fig. 1. Alignment of monomeric four-domain glyoxalases I. Residues contributing to GSH binding in the human enzyme [4] are boxed. Metal-
binding residues are shadowed. Due to gene duplication these residues are present two times (see also Fig. 2). The Arabidopsis protein (identi-
¢ed in this report) is predicted to possess a long N-terminal plant-speci¢c signal sequence which is not shown here. GenBank accession num-
bers are given in parentheses: Ag, Anopheles gambiae str. PEST (EAA00341); At, Arabidopsis thaliana (AAL84986); Pf, Plasmodium falciparum
(AF486284, this paper); Py, Plasmodium yoelii (EAA18062); Sc, Saccharomyces cerevisiae (CAA67622).
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man Glx I [4,26] the active site is located at the dimer inter-
face (see Fig. 2B) where side chains from both subunits inter-
act with GSH and the metal ion, which is zinc in Glx I pro-
teins from most organisms but nickel in the E. coli enzyme
[27].
In yeasts [7], a number of plants [4,8,9] and P. falciparum
(this report) Glx I consists of four domains. Further in silico
analyses enabled us to identify four-domain-type Glx I also in
other Plasmodia (P. yoelii, P. vivax, P. chabaudi) and in in-
sects, including the malaria mosquito Anopheles gambiae. As
Fig. 2. Schemes of monomeric PfGlx I and homodimeric human Glx I. The LKLLL structure motif is indicated [4], residues involved in metal
binding (derived from crystallographic data for human Glx I and derived from secondary structure predictions and alignments in the case of
PfGlx I) are numbered according to the sequences of the two proteins. The C-terminal fragment of PfGlx I probably forms a dimeric structure
like human Glx I.
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indicated in Figs. 1 and 2, the N-terminal (residues 1^172) and
the C-terminal part (residues 173^356) of PfGlx I are highly
homologous to each other as well as to human Glx I. The
residues contributing to glutathione binding in hGlx I corre-
spond to R22/R186, F52/F214, N95/N276, and F151/F335 in
the two halves of PfGlx I. The catalytic loop in the human
enzyme which is essential for substrate binding and product
release [28,29] is conserved in both PfGlx I fragments (see Fig.
1). Based on the putative structure of PfGlx I (Fig. 2A) and
the homology with hGlx I [30], two Zn2þ-binding sites can be
identi¢ed in PfGlx I. They are represented by Q18, E91, H299,
and E345 for one metal ion and by Q182, E272, H115, and
E161 for the second one. It is noteworthy that one metal-
binding site is contributed by domains 1 and 4 and the other
one by domains 2 and 3 of PfGlx I (Fig. 2A).
All residues representing the binding sites for glutathione
and zinc ions, respectively, as well as the catalytic loop of
human Glx I are conserved in either half of PfGlx I (Fig.
1). Secondary structure prediction [31] and modeling of the
tertiary structure of PfGlx I (Swiss Prot, [32]) con¢rmed these
similarities among the three structures.
3.2. Recombinant PfGlx I
PCR ampli¢cation, cloning and sequencing of the putative
glx I gene of P. falciparum resulted in a nucleotide sequence
which was in full agreement with the gene (1071 bp) of the
genomic database (Table 1).
The gene was overexpressed in E. coli with a yield of 5 mg
l31 cell culture (OD600 = 2.2). The hexahistidyl-tagged re-
combinant protein of 43.6 kDa was puri¢ed over Ni^NTA
agarose and proven to be pure and of correct size by SDS^
PAGE and Western blot analysis (see Fig. 3). As shown by gel
¢ltration over a calibrated Sephadex G-200 column PfGlx I is
present and active as a monomeric protein (Table 1).
PfGlx I was found to catalyze the intramolecular dispro-
portionation of the hemithioacetal formed by methylglyoxal
(2 mM) and glutathione (1 mM) to SLG. A pH pro¢le carried
out in 100 mM potassium phosphate, 100 mM KCl indicated
an optimum at pH 7.8. Since the spontaneous reaction be-
tween GSH and methylglyoxal also increased with increasing
pH and in order to enable comparability with previous studies
all further assays were carried out at pH 7.0 and 25‡C.
For determining the KM values of the hemithioacetals, the
concentration of GSH (30 WM to 1 mM) was systematically
varied in the presence of excess (30 mM) 2-oxoaldehyde. The
two reactants were preincubated for 15 min to guarantee com-
plete formation of the hemithioacetal [23] before the assay
was started with enzyme. The kinetic characteristics of PfGlx
I are given in Table 1.
3.3. Inhibition studies
Di¡erent known Glx I inhibitors [1,15^17] were studied on
the recombinant P. falciparum enzyme. PfGlx I was compet-
itively inhibited by the physiologic nitric oxide carrier S-nitro-
soglutathione (Ki = 190 WM) which is known to reach high
levels in cerebral malaria, by methylglutathione (Ki = 170
Table 1
Characteristics of PfGlx I
Accession number GenBank1 AF486284
Location in P. falciparum genome Chromosome 11
Genomic DNA numbering bp 527107^528177
GenBank1 AL034558
mRNA 1071 bp (with start and stop codon)
Amino acids 356
Molecular mass 42.3 kDa
Molecular mass (with His-tag) 43.6 kDa
Isoelectric point (without His-tag) 5.84
O at 280 nm 56.8 mM31 cm31
Bound metal ion Zn2þ and/or Ni2þ
pH optimum 7.8
Speci¢c activity 90 U mg31
kcat 4000 min31
KM for glutathione^methylglyoxal hemithioacetal 77T 15 WM
kcat/KM 0.9U106 M31 s31
KM for glutathione^glyoxal hemithioacetal 580T 40 WM
Ki of S-nitrosoglutathione 190 WM
Ki of methylglutathione 170 WM
Ki of S-p-nitrosobenzylglutathione 60 WM
Activity of the C-terminal fragment 3.1 U mg31
Activity in P. falciparum trophozoite extracts 70^140 mU mg31 protein
Down to the line ‘O at 280 nm’, the data were deduced from the DNA sequence. The experimental data from ‘bound metal ion’ to the ‘Ki val-
ues’ refer to the puri¢ed recombinant His-tagged protein. The activity in extracts from isolated parasites represents the authentic enzyme.
Fig. 3. Western blots of PfGlx I and its fragments. Lane 1: recom-
binantly expressed N-terminal fragment of PfGlx I (200 ng); lane 2:
recombinant C-terminal fragment of PfGlx I (200 ng); lane 3:
empty; lane 4: recombinant PfGlx I (150 ng); lane 5: extract of
P. falciparum strain FCR3 (11 Wg total protein). The molecular
mass standard is given on the right-hand side. Due to the His-tag,
the recombinant enzyme is 1^2 kDa larger than the authentic pro-
tein present in parasite extracts.
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WM), and by S-p-nitrobenzylglutathione (Ki = 60 WM). These
data represent a basis for further inhibitor development aim-
ing at speci¢c inactivation of the parasite enzyme.
3.4. Metal binding to Glx I
As determined by atom absorption spectroscopy, isolated
recombinant Glx I contained zinc and nickel in varying molar
ratios: 0.4^1.2 zinc and up to 0.1 nickel ions per monomer, the
values varying among di¡erent preparations. This indicated
that the enzyme was not fully saturated with metal ions. Ac-
cordingly, the enzyme preparation with 0.6 zinc ions per Glx I
was found to be dose dependently activated by 10 min preincu-
bation with di¡erent metal salts. Zinc and Mn ions at 250 WM
increased enzyme activity by a factor of 2.7 and 1.5, respec-
tively; 20 WM NiCl2 activated the protein 2.9-fold.
When trying to saturate the protein containing 0.6 zinc ions
with Ni2þ ions, a Glx I containing 1.3 T 0.3 nickel and
0.6T 0.1 zinc ions was obtained. When saturating with ZnCl2
the resulting protein contained 1.4T 0.5 zinc ions and 0.05
nickel ions. These results indicate that the enzyme can bind
both Ni2þ and Zn2þ but that Ni2þ does not displace zinc ions.
Together with the predicted structure of the protein (Fig. 2)
these experimental data furthermore con¢rmed a metal-bind-
ing stoichiometry of 2.
3.5. Glx I in P. falciparum
In extracts from isolated P. falciparum trophozoites the
speci¢c activity of Glx I was 70 mU mg31 in the K1 strain
and 140 mU mg31 in the FCR3 strain. The speci¢c reaction of
PfGlx I with rabbit IgG raised against the recombinant pro-
tein was demonstrated by Western blotting (Fig. 3).
3.6. Structure duplication
The hypothesis that PfGlx I has evolved from two homol-
ogous parts, each of which resembling a functional small Glx,
was further addressed using a protein engineering approach.
The N-terminal half (comprising residues 1^172) and the
C-terminal half (comprising residues 173^356) were recombi-
nantly produced as His-tagged proteins. Western blot analysis
of the products resulted in single bands of expected sizes (Fig.
3, left lanes). The N-terminal fragment was poorly soluble and
thus remained largely in the cell pellet. In contrast, the C-ter-
minal fragment was puri¢ed to homogeneity with a yield of
0.3 mg l31 (OD600 = 1.8).
In the presence of 100 WM ZnCl2 the speci¢c activity of the
C-terminal half was determined to be 3.1 U mg31, which
corresponds to 3.4% of wild-type activity. The KM for the
glutathione^methylglyoxal hemithioacetal was approximately
100 WM, which is very similar to the wild-type. FPLC analysis
(gel ¢ltration over a calibrated Superdex 75 column) of the
C-terminal fragment in the presence of 100 WM ZnCl2 sug-
gested a dimer/monomer equilibrium, the peaks appearing at
28 and 46 kDa. The assumption that the dimer represents the
active species was veri¢ed by enzyme assays where the activity
was studied as a function of protein concentration in the
range of 50^1000 nM C-terminal fragment. The results are
consistent with the monomer/dimer equilibrium 2 ZnM
=Zn2D, the dissociation constant K= [ZnM]2/[Zn2D] being
28 WM. This suggests strongly that the enzymatic character-
istics of the C-fragment dimer are similar to those of intact
Glx I. The most plausible structure of the dimeric C-fragment
is similar to that of Human Glx I (Fig. 2B). Thus the C-frag-
ment of Glx I is suitable for screening tests where we expect to
identify structure-dissociating agents as inhibitors of PfGlx I.
Taken together, our ¢ndings indicate that the ancestor of
PfGlx I was active as a homodimer (represented by the dimer
of the C-terminal fragment) before gene duplication and fu-
sion gave rise to a four-domain monomer.
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